Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Ya a partnership.. some say no real news for several months or more or NOTHING beyond Rett but a partnership announcement could come any day and would push us 10 dollars higher in an instant :)
Ok ok but today go baby go want to run down to the pound and buy a dozen lobsters and celebrate ,,, celebrate .. cell—- a — berate market down up to15? Pennies
PW
You have been a staunch supporter of Chris and the anavex team , I hope you are richly blessed . We were given a gift in 21 ( we should have accepted it and ran for the hills but dummies like me held on for more .. I have cut my holdings in Avxl but still hold enough to save my pride and perhaps a 911 but we need revenue which means approval somewhere .. may the force be with the CEO and the BOD and retail investors
I keep smelling what seems like the barbecue but the burgers and steaks still seem like a mirage
Did you see this coming ? 2 takeaways… the company really does believe in their data and two .. the lack of serious AE’s and ease of administering is BIG !! Lol
NEW YORK, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders announced today that representatives of Anavex met with team members of the European Medicines Agency (EMA).??
These meetings discussed the debilitating pathology of Alzheimer’s disease and Anavex’s blarcamesine (ANAVEX®2-73) Alzheimer’s disease clinical program results, including data obtained in the ANAVEX®2-73-AD-004 study.
Pursuant to discussion at the meetings, Anavex initiated the process for submitting a Marketing Authorisation application to the EMA with the submission of the Centralised Procedure request with the goal of the Authorisation allowing direct access to the market of the European Union for oral blarcamesine for the treatment of Alzheimer’s disease.
Anavex’s goal is to take care of patients in a patient-centric way with the preference for convenient oral treatment options for Alzheimer’s disease not requiring complex logistics resources and added personnel for drug administration and monitoring for brain edema and brain bleeds.
Severe symptoms in relation to Amyloid-Related Imaging Abnormalities (ARIA) is a known risk factor for Alzheimer’s patients taking the class of drugs called monoclonal antibodies, and requires constant and repeated MRI examination, for which not all regions in Europe are currently sufficiently prepared and equipped for in addition to the requirement to address affordability and inequalities in patient access within European Union countries.1,2
“We look forward to working together with the team from EMA,” said David Goldberger, RPh, MLS, Senior Vice President Regulatory Affairs at Anavex. “We continue to work towards fulfilling our purpose of improving patients' lives with oral blarcamesine not requiring any complex additional procedures for the treatment of people with Alzheimer’s disease.”
There are an estimated 7 million people in Europe with Alzheimer’s disease, a number expected to double by 2030, according to the European Brain Council.3
The World Health Organization (WHO) estimated the cost in Europe of caring for people with dementia, including Alzheimer's disease, at $439 billion, or $31,144 per person in 2019. That includes hospital care, medicines, diagnostics, informal caregiver time, community services and long-term care facility costs.4,5
“There remains an urgent need for convenient once-daily oral treatment options for Alzheimer’s disease, and Anavex is moving forward to potentially addressing the preference for simple patient-centered administrations and shared decision-making,” said Christopher U Missling, PhD, President and Chief Executive Officer at Anavex.
In addition to significant improvement in dementia symptoms, blarcamesine demonstrated reduction of pathological aggregation of amyloid in early Alzheimer’s disease as well reduction of brain volume loss, a well-known marker of neurodegeneration.
Data from the blarcamesine in Alzheimer’s disease Phase 2b/3 randomized clinical trial will be published in an upcoming peer-reviewed journa
Because the fact is we do have a large short position against the shares :)
Perhaps today is the day with additional releases of material info is the start of our quick and big short squeeze or maybe a longer slower uptrend but still hoping for ‘ other ‘ announcements
Been hearing this message for years
Ya really would love to be a fly on the wall . Is there any urgency to get this data out ? What are the reasons for the tardiness? Are they even in the office today ?
I never expected Chris to mislead to the extent he has . .. to speak and create expectations based on what he actually says and articulates in press releases and those expectations are never fulfilled on specifically two different timelines A ) the timelines that have been generally accepted based on hundreds of prior trials completed last patient dosed and release of TLD and B) his own stated timelines that seemingly are never met and additionally, seem to be grossly late compared to traditional timelines
Now we know why it’s so easy to boil a frog alive .. we are just as smart or just as stupid as a frog
About to explode and what ? Cease to exist ! I’ve come to realize that investing and trading around interest rate risks .”, the fed , and all other current events is demonstrably easier than investing and trading around the disturbing and utter opaqueness of Avxl and Chris .. I’ve reduced my exposure to just 1.5 percent of my overall portfolio and just an observation of mine ; those who pump always have money to buy lower and lower
Still disappointing that AVXL trades so poorly and particularly now with SAVA trading at a market cap twice of that of AVXL with its warts and inconsistencies
I don’t believe a word you say ..
I’ve been reading posts like this for 8 years now ( that’s a lot of days ) we’ve been beaten up , beaten down , beaten all around .. even if we bounce 100 percent now won’t cover inflation costs , gas costs , opportunity costs , funeral costs !!
I sold a bunch at 10.41 back in Feb. really did not wish that I could double my shares 8 months later but right now if I double my shares don’t know if that is really smart or really stupid . I did learn my multiplication tables as a 6 year old and learned 5 x0 is zero and 10x0 is zero so twice the shares x zero is still zero so maybe I’ll wait a while until the crystal ball is a lot more definitive
Nothing to talk about , nothing to discuss , nothing to muse about , nothing to be proud about , nothing to feel good about , nothing to validate about , nothing to vindicate , nothing . Maybe that’s why he’s been quiet
If we had ‘ the goods ‘ then keeping it hid under a rock is a strange way to manage a young biotech . I mean missling can’t control the 10 year bond and interest rates and equity markets but he can control dissemination of relevant data in a timely manner and packaged in a way that is consistent with accepted norms , but that ain’t happening and why at this moment in 8 years he has not created a single penny of investor value .. :(
I really dont know the strategy . Rather startling to spend money , create trials , provide trial data and state success but 3 years later .. nothing , nothing , nothing !! PDD !!! What is the strategy ? Well , whatever it is it ain’t working and in the corporate world CEO’s get replaced
I agree .. thot PM would increase our odds of approval for an least a sub group of patients creating revenue and appreciation of stock price nada , nada
Ha .. finally .. your best post in quite a while
Yes that is true . Missling has made statements that has created expectations . He knows the consequences of false and misleading claims , comments , and statements. Hopefully , AVXL will deliver data results consistent with expectations
Well if the results were leakin and terrible the stock would be falling quicker .. however there is zero confidence in the market .. any reasonable investor would expect TLR by now and Missling / Company is quiet on everything so and maybe MM’s are driving price down so certain entities can load up on cheaper shares plus this or that but certainly hoping that the company will demonstrate prudence and sustainability by communicating in a timely manner
My stockbroker told me way back in the 1980’s when he started as a trader on the Toronto stock exchange one of his first jobs was to trigger stop loss orders
Take no offence but , 13 followers ? Well that’s great !! You know treating disease upstream with minimal AE , and all other stated milestones and hot air ( I really want to believe ) should be desired by the market but especially suitors with the money to buy or partner .. Missling needs to go ..
I did a bunch in Feb at 10.40 and more iat 9 but not some back at .7.85 . This last 12 months , so much anticipation and expectation with Rett trials and AD Trial readout ( should have learned from PDD fizzle
But clearly , you have stated your belief of chance of success is minimal so obviously to state that the trial is a success would contradict your several thousand last posts so i don’t know … ? I guess I’ll make up my own mind about success or failure lol
Ya it’s hard for us longs to loose more than 6.30 a share and cash must represent 1.50 so ya most of our losses have occurred and in fact a drop to 2 is no more hurtful than the drop from 10.50 so ya one more chopped off finger is hardly no worse than the 2 we already lost
That would be so nice . Yes Nancy . Even a hologram or AI generated image that can persuade and speak softly ! But you know it’s darkest before the Dawn so shareholders simply have to wait to see their bucket of gold grow . The markets and bios are not for everyone.. I took possession of one of those RX 500 H fully loaded in June .. anavex was supposed to land me a ‘Nancy ‘ and a 911 turbo .. everyday I get older it seems I will have to settle for a hologram . Com’on anavex and team . Throw us ( me ) a bone to chew on
Yes the biotechs are not user friendly .. I need to find a pretty young thing so I can forget about this ugly dog! That might work for you too :)
As we all know and knew from the start that 2-73 was not a miracle drug that would miraculously cure AD but I (we) hoped that 2-73 would help many with varying degrees of effectiveness, beating the SOC , with limited AE’s. I think it is reasonable to think if the Rett results are unambiguously good and trial met all required protocols then we have a little more confidence with the AD trial data so Rett results are extremely critical . Missling has intimated from the past that 2-73 is better treating Rett than Daybue ( is that the name ) so hopefully he delivers the goods ..
Biotech has been in the doldrums since the high of mid 2021 adding to the downward pressure on most biotech equities so not much surprise at our share price .. we still need positive developments with data release and FDA communications to move this share price north and that rests solely on Missling and the team that the BOD has assembled
Well I would take 18 and move on .. I would have thot by now with trials on several indications seemingly with intriguing data that an offer or at least a rumour of an offer or courtship or buyout would have been made spiking the share price .. but nothing , nada , nada , nada , !! Maybe this coming week lol
Well you know , at any given point in time the share price and market cap may not ( probably does not ) represent the true intrinsic value of that particular equity . That’s the nature of the volatilite stock market … a partnership or any decision by other entities that creates income for the company will propel share price higher and the market and investment gurus will determine appropriate multiples and share price .. we wait and wait and wait .
Our pixie dust got all used up back in 2021 .. so it seems
It seems like just facts in this post . The new FDA hires just reasonably would bring some intellectual inspiration to the process . The fact that the SOC is so ineffective bodes well for 2-73 but the team’s got to execute and is the FDA in big pharma’s pockets ? Probably .
There was a time way way back years ago when I thought this message board and mucho followers would be an asset to the share price but it’s a liability instead. The alpha dogs always pound good news into bad news ! Bot 1500 Disney at 83 few days go so maybe a lobster celebration tonight … I’m hopeful by next spring ( well I don’t need the money until spring ) that we will be significantly higher than now .. Rett will be released and pray with all fingers and toes that it works for the girls and additionally concrete direction on AD with known timelines with FDA guidance
I knew way back it may take scientific creativity to pull this very drug across the finish line .. subjective questions and placebo effects can always cause some ambiguity and FUD bashing but the MRI readouts on brain volumes and plasma concentrates are absolutely great objective measurements that supports the company’s claims … :)
Ya that’s ok in the absence of meaningful or ANY news the board fills up with other stuff .. ya check to see if there is news and if no news move on to something else that is more productive
SAVA moving up 20 percent in last few days again increasing the spread between the two companies . Obviously, little disappointing for AVXL stock holders
Ya well sold a bunch at 9 bot back in at 7.85 .. too many traders but still traders can’t stop missling from executing and communicating.. but with a MC at 600M and 150M in cash it’s debatable how much or how little premium there is in the stock price